Gritstone bio rallies after U.S. patent win for mRNA-based vaccine tech

Dec. 13, 2022 10:08 AM ETGritstone bio, Inc. (GRTS)CMXHF, ARCT, CSLLYBy: Dulan Lokuwithana, SA News Editor

Single strand ribonucleic acid, RNA research

luismmolina/iStock via Getty Images

  • Clinical-stage biotech Gritstone bio (NASDAQ:GRTS) added ~13% in the morning hours Tuesday after the company announced that the U.S. regulators issued two new patents related to its self-amplifying mRNA (samRNA) vaccine platform technology.
  • The U.S. Patent No. 11,504,421 issued

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.